Does the HFA/ICOS tool overestimate the risk of cardiovascular toxicities in oncologic patients scheduled to receive anti-VEGF agents?

Letter to the Editor TheHeart Failure Association of the European Society of Cardiology (HFA) and the International Cardio-Oncology Society (ICOS) recently proposed the use of a chartbased tool for the baseline cardiovascular risk assessment of oncologic patients scheduled to receive anticancer treatments associated with cardiovascular toxicities. Among these drugs are antivascular endothelial growth factor (anti-VEGF) agents, which may cause arterial and venous thrombo-embolic events or heart failure.